Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136262 | 0.91 | TLR7 (0.41) | — | |
| SCHEMBL5135283 | 0.89 | NPC1 (0.36) | LTB4R2NPC1SMN1; SMN2TRPM8 | |
| SCHEMBL5137355 | 0.88 | TSHR (0.39) | TSHR | |
| SCHEMBL5134818 | 0.88 | TSHR (0.39) | TSHR | |
| SCHEMBL5134753 | 0.87 | STAT3 (0.40) | LTB4R2TSHR | |
| SCHEMBL5135309 | 0.86 | TLR7 (0.41) | — | |
| SCHEMBL5135943 | 0.86 | C5AR1 (0.36) | TSHR | |
| SCHEMBL5134566 | 0.85 | TSHR (0.41) | LTB4R2NPC1TSHR | |
| SCHEMBL5137583 | 0.84 | HSP90AA1 (0.39) | TSHRGABRA1 | |
| SCHEMBL5135337 | 0.83 | TSHR (0.37) | LTB4R2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |